Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.13% | 3.28% | |||
| Gross Profit | 3.13% | -3.28% | |||
| SG&A Expenses | -4.00% | 16.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.39% | 6.78% | |||
| Operating Income | 3.39% | -6.78% | |||
| Income Before Tax | 3.46% | -3.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.46% | -3.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.46% | -3.14% | |||
| EBIT | 3.39% | -6.78% | |||
| EBITDA | 3.41% | -6.83% | |||
| EPS Basic | 9.20% | 17.62% | |||
| Normalized Basic EPS | 9.00% | 17.41% | |||
| EPS Diluted | 9.20% | 17.62% | |||
| Normalized Diluted EPS | 9.00% | 17.41% | |||
| Average Basic Shares Outstanding | 6.32% | 25.21% | |||
| Average Diluted Shares Outstanding | 6.32% | 25.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||